In a more recent example, oral ALK kinase inhibitors became first line therapy for ALK-fusion positive non-small cell lung cancer after several studies showed similar efficacy and significantly improved side effects and quality of life for patients on ALK inhibitors compared to chemotherapy (3). Here, ALK is linked to non-small cell lung carcinoma.